Arcoma har fått en ramorder värd 38 MSEK från amerikanska Virtual Imaging. Leveranser kommer att ske under kommande 12 månader, och planeras bidra till omsättningen med ca 3,5 MSEK under Q2 2018 och med minst 3 MSEK under Q3 2018. Virtual Imaging ägs av Canon och säljer Arcomas röntgensystem både via distributörer och direkt till slutkund i USA och Kanada.
Ascelia Pharma is a Swedish-based specialty oncology drug development company with a late stage pipeline of products. The equity injection of SEK 60 million will be used to advance the development of Ascelia Pharma’s drug candidates – Mangoral® and Oncoral.
“I am highly satisfied with the support from both current and new shareholders and their confidence in Ascelia Pharma and our promising drug candidates. The funding will enable us to finalize preparations for the Mangoral® Phase III clinical study as well as complete the ongoing Oncoral Phase I study”, says Magnus Corfitzen, Chief Executive Officer of Ascelia Pharma
Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumordirected immunotherapy, and Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced the presentation of new preclinical data supporting ALG.APV-527 as a promising new immunotherapeutic candidate for the treatment of a variety of 5T4-expressing solid tumors.
ALG.APV-527 is designed to simultaneously target 5T4 and the co-stimulatory receptor 4-1BB (CD137) to promote potent, tumor-directed immune T-cell activation. 5T4 is a well-defined tumor antigen expressed on many different types of malignancies including, non-small cell lung, renal, pancreas, prostate, breast, colorectal, gastric, ovarian and cervical cancers. Conversely, 5T4 has limited expression on normal tissues, making it an attractive target for cancer immunotherapy.
Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines, and Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, announced today that Mymetics SA, the Swiss subsidiary of Mymetics Corporation and Anergis SA have entered into a Research Collaboration project.
The pre-clinical study program will evaluate the immunogenicity profile of the Anergis peptides designed to treat birch allergy (the Bet v1 COPs) when presented on Mymetics’ proprietary virosomes, with or without undisclosed TLR ligands or other adjuvants, and will compare the results to Anergis’ AllerT product combination (Bet v1 COPs with aluminum hydroxide).
Sunstone Capital today announces that H. Lundbeck A/S (Lundbeck) will acquire Sunstone portfolio company Prexton Therapeutics BV (Prexton).
Prexton develops innovative drugs to improve the quality of life of people who suffer from Parkinson’s disease and other brain disorders. Prexton’s lead compound Foliglurax is currently in clinical phase II for symptomatic treatment of OFF-time reduction in Parkinson’s disease and dyskinesia (involuntary muscle movements). Prexton is located in Oss (the Netherlands) and Geneva (Switzerland).
Under the terms of the agreement Lundbeck will pay €100 million in cash upfront to Prexton’s current owners and is furthermore required to pay additional €805 million in development, regulatory and sales milestones depending on successful outcome of certain undisclosed milestones.